Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.44 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3558511 | 0.89 | ALDH1A1 (0.46) | SMN1; SMN2DDB1CRBNALDH1A1MEN1 | |
| SCHEMBL25670728 | 0.88 | CYP2D6 (0.53) | ALDH1A1MEN1KMT2A | |
| SCHEMBL27527934 | 0.86 | ALDH1A1 (0.46) | DDB1CRBNALDH1A1 | |
| SCHEMBL16488071 | 0.85 | OPRM1 (0.51) | DDB1CRBNALDH1A1 | |
| SCHEMBL3560767 | 0.84 | ALDH1A1 (0.48) | CYP2C19SMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL3563828 | 0.83 | MEN1 (0.56) | MEN1KMT2ANPSR1 | |
| SCHEMBL3104656 | 0.82 | MEN1 (0.50) | SMN1; SMN2MEN1KMT2ANPSR1 | |
| SCHEMBL629912 | 0.82 | MEN1 (0.54) | CYP2C19SMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL12026430 | 0.81 | CHRM1 (0.47) | DDB1CRBNALDH1A1 | |
| SCHEMBL18692576 | 0.81 | ALDH1A1 (0.53) | DDB1CRBNALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7750161-B2 | Pyridine derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2010-07-06 | — | — | US | disclosed |
| US-20070043081-A1 | Novel pyridine derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2007-02-22 | — | — | US | disclosed |
| EP-1670470-A1 | PYRIDINE DERIVATIVES AND USE THEREOF AS UROTENSIN II ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005030209-A1 | PYRIDINE DERIVATIVES AND USE THEREOF AS UROTENSIN II ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043081-A1 | Novel pyridine derivatives | P2RY4, P2RX6, P2RX4 | CYP2C19 595/4885SMN1; SMN2 3430/4885DDB1 4839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.